BioNTech (BNTX) Q4 2024 earnings summary

Executive summary

• Achieved 2024 revenues of €2.8 billion, meeting guidance midpoint, despite lower COVID-19 vaccine demand and partner write-downs.

• Maintained a strong cash position of €17.4 billion at year-end 2024, prior to major acquisition and settlement payments.

• Advanced oncology pipeline with over 20 active Phase 2 and 3 trials, including BNT327 and mRNA immunotherapies, with significant data expected in 2025.

• Closed the Biotheus acquisition, securing global control of BNT327 and expanding antibody and ADC capabilities in China.

• Continued global leadership in COVID-19 vaccines with Pfizer, launching new adapted vaccines and progressing next-generation candidates.

Financial highlights

• 2024 revenues: €2.75–2.8 billion, down from €3.82–3.8 billion in 2023, mainly due to reduced COVID-19 vaccine demand.

• Net loss for 2024: €665–665.3 million, compared to a net profit of €930–930.3 million in 2023.

• R&D expenses: €2.25–2.3 billion in 2024, up from €1.78–1.8 billion in 2023, reflecting investment in late-stage programs.

• SG&A expenses: €599 million in 2024, up from €557.7–558 million in 2023, driven by commercial build-out.

• Negative other operating results of €670.9–671 million, mainly due to legal settlements and related expenses.

Outlook and guidance

• 2025 revenue guidance: €1.7–2.2 billion, assuming stable vaccination rates and market share, with revenue phasing concentrated in the last 3–4 months.

• R&D expenses expected to rise to €2.6–2.8 billion in 2025, focused on priority late-stage programs.

• SG&A expenses projected at €650–750 million, reflecting continued commercial expansion.

• Capital expenditures for 2025 expected at €250–350 million, supporting manufacturing and IT investments.

• No positive net income expected for 2025.